Ⅰ类HDAC在慢性呼吸系统疾病中的研究进展

刘喜悦, 薛小丽, 李芳伟

PDF(497 KB)
PDF(497 KB)
重庆医科大学学报 ›› 2024, Vol. 49 ›› Issue (10) : 1051-1054. DOI: 10.13406/j.cnki.cyxb.003601
综述

Ⅰ类HDAC在慢性呼吸系统疾病中的研究进展

作者信息 +

Research advances in class Ⅰ histone deacetylases in chronic respiratory diseases

Author information +
History +

摘要

组蛋白的乙酰化及去乙酰化修饰在许多的病理生理过程中起重要作用,与许多疾病的发生发展密切相关。此修饰过程是动态可逆的,由组蛋白乙酰化酶(histone acetyltransferase,HAT)与组蛋白去乙酰化酶(histone deacetylase,HDAC)共同催化完成。不同亚型的HDAC通过不同的机制参与疾病的发生发展。慢性呼吸系统疾病是造成非传染性疾病巨大负担的重要因素,但是缺乏根治的方法。支气管哮喘、慢性阻塞性肺疾病、间质性肺疾病、肺动脉高压是最常见的慢性呼吸系统疾病,已有研究证实Ⅰ类HDAC在上述4种疾病的发病过程中起重要作用。本文通过对Ⅰ类HDAC在这4种疾病中的分子机制的研究进行综述,为其治疗提供新思路和靶点。

Abstract

The acetylation and deacetylation modifications of histones play an important role in many pathophysiological processes and are closely associated with the development and progression of many diseases. This modification process is dynamic and reversible is jointly catalyzed by histone acetylase and histone deacetylase(HDAC). Different subtypes of HDAC participate in the development and progression of diseases through different mechanisms. Chronic respiratory diseases are an important factor causing the huge burden of non-communicable diseases,but there is still a lack of radical treatment methods. Bronchial asthma,chronic obstructive pulmonary disease,interstitial lung disease,and pulmonary hypertension are the most common chronic respiratory diseases,and studies have confirmed that class I HDACs play an important role in the pathogenesis of the above four diseases. This article reviews the research advances in the molecular mechanism of class I HDACs in these four diseases,so as to provides new ideas and targets for treatment.

关键词

组蛋白去乙酰化酶 / 支气管哮喘 / 慢性阻塞性肺疾病 / 间质性肺疾病 / 肺动脉高压

Key words

histone deacetylase / bronchial asthma / chronic obstructive pulmonary disease / interstitial lung disease / pulmonary hypertension

中图分类号

R562.2

引用本文

导出引用
刘喜悦 , 薛小丽 , 李芳伟. Ⅰ类HDAC在慢性呼吸系统疾病中的研究进展. 重庆医科大学学报. 2024, 49(10): 1051-1054 https://doi.org/10.13406/j.cnki.cyxb.003601
Liu Xiyue, Xue Xiaoli, Li Fangwei. Research advances in class Ⅰ histone deacetylases in chronic respiratory diseases[J]. Journal of Chongqing Medical University. 2024, 49(10): 1051-1054 https://doi.org/10.13406/j.cnki.cyxb.003601

参考文献

1
Bisserier M Janostiak R Lezoualc'h F,et al. Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease[J]. Vasc Biol20202(1):17-34.
2
Chronic Respiratory Disease Collaborators GBD. Prevalence and attributable health burden of chronic respiratory diseases,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Respir Med20208(6):585-596.
3
Choi JH Oh SW Kang MS,et al. Trichostatin A attenuates airway inflammation in mouse asthma model[J]. Clin Exp Allergy200535(1):89-96.
4
Ito K Caramori G Lim S,et al. Expression and activity of histone deacetylases in human asthmatic airways[J]. Am J Respir Crit Care Med2002166(3):392-396.
5
Su XM Ren Y Li ML,et al. Performance evaluation of histone deacetylases in lungs of mice exposed to ovalbumin aerosols[J]. J Physiol Pharmacol201869(2):26402.
6
Peng XR Huang MY Zhao WQ,et al. RAGE mediates airway inflammation via the HDAC1 pathway in a toluene diisocyanate-induced murine asthma model[J]. BMC Pulm Med202222(1):61.
7
Lai TW Wu MD Zhang C,et al. HDAC2 attenuates airway inflammation by suppressing IL-17A production in HDM-challenged mice[J]. Am J Physiol Lung Cell Mol Physiol2019316(1):269-279.
8
Li ML Su XM Ren Y,et al. HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization[J]. Respir Res202021(1):62.
9
Masjedy A Salesi M Ahmadi A,et al. Association between single-nucleotide polymorphism of cytokines genes and chronic obstructive pulmonary disease:a systematic review and meta-analysis[J]. Cytokine2023171:156352.
10
Tan CT Xuan LL Cao SH,et al. Decreased histone deacetylase 2 (HDAC2) in peripheral blood monocytes(PBMCs) of COPD patients[J]. PLoS One201611(1):e0147380.
11
Mercado N Thimmulappa R Thomas CMR,et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress[J]. Biochem Biophys Res Commun2011406(2):292-298.
12
Hodge G Jersmann H Tran HB,et al. Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes[J]. Respir Res201516(1):130.
13
Lai TW Tian BP Cao C,et al. HDAC2 suppresses IL17A-mediated airway remodeling in human and experimental modeling of COPD[J]. Chest2018153(4):863-875.
14
Winkler AR Nocka KN Williams CMM. Smoke exposure of human macrophages reduces HDAC3 activity,resulting in enhanced inflammatory cytokine production[J]. Pulm Pharmacol Ther201225(4):286-292.
15
Zhang M Hei R Zhou Z,et al. Macrophage polarization involved the inflammation of chronic obstructive pulmonary disease by S1P/HDAC1 signaling[J]. Am J Cancer Res202313(9):4478-4489.
16
Racanelli AC Kikkers SA Choi AMK,et al. Autophagy and inflammation in chronic respiratory disease[J]. Autophagy201814(2):221-232.
17
Saito S Zhuang Y Suzuki T,et al. HDAC8 inhibition ameliorates pulmonary fibrosis[J]. Am J Physiol Lung Cell Mol Physiol2019316(1):175-186.
18
Chen F Gao Q Zhang LJ,et al. Inhibiting HDAC3(histone deacetylase 3) aberration and the resultant Nrf2(nuclear factor erythroid-derived 2-related factor-2) repression mitigates pulmonary fibrosis[J]. Hypertension202178(2):15-25.
19
Korfei M Skwarna S Henneke I,et al. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis[J]. Thorax201570(11):1022-1032.
20
Rubio K Singh I Dobersch S,et al. Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis[J]. Nat Commun201910:2229.
21
Toscano-Marquez F Romero Y Espina-Ordoñez M,et al. Absence of HDAC3 by matrix stiffness promotes chromatin remodeling and fibroblast activation in idiopathic pulmonary fibrosis[J].Cells202312(7):1020.
22
Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension[J]. J Clin Invest2012122(12):4306-4313.
23
Li M Riddle SR Frid MG,et al. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension[J]. J Immunol2011187(5):2711-2722.
24
Yang QW Sun M Ramchandran R,et al. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension:role of epigenetic regulation[J]. Vascul Pharmacol201573:20-31.
25
Nozik-Grayck E Woods C Stearman RS,et al. Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension[J]. Am J Physiol Lung Cell Mol Physiol2016311(1):124-134.
26
Yu QJ Tai YY Tang Y,et al. BOLA(BolA family member 3) deficiency controls endothelial metabolism and glycine homeostasis in pulmonary hypertension[J]. Circulation2019139(19):2238-2255.
27
Li FW Wang D Wang H,et al. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a[J]. Respir Res202122(1):239.
28
Chelladurai P Dabral S Basineni SR,et al. Isoform-specific characterization of class Ⅰ histone deacetylases and their therapeutic modulation in pulmonary hypertension[J]. Sci Rep202010(1):12864.

基金

国家自然科学基金资助项目(81960014;82360014)
兰州大学第二医院“萃英科技创新”计划资助项目(2020QN-23)
甘肃省高等学校创新基金资助项目(2021B-028)

评论

PDF(497 KB)

Accesses

Citation

Detail

段落导航
相关文章

/